SCHEMBL14691305

SCHEMBL14691305

C=CCOC1Cc2c(OCc3ccccc3)cc(OCc3ccccc3)cc2OC1c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ABCB1 P08183 6/20 0.40
▸ F10 P00742 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ PIN1 Q13526 1/20 0.34
▸ MAOB P27338 2/20 0.34
▸ MAOA P21397 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18427309 0.90 STING1 (0.46) STING1MEN1MAPTKMT2AABCB1
SCHEMBL18427349 0.90 STING1 (0.46) STING1MEN1MAPTKMT2AABCB1
SCHEMBL5267159 0.90 STING1 (0.46) STING1MEN1MAPTKMT2AABCB1
SCHEMBL30054526 0.85 ABCB1 (0.47) STING1MEN1MAPTKMT2AABCB1
SCHEMBL30054293 0.85 ABCB1 (0.47) STING1MEN1MAPTKMT2AABCB1
SCHEMBL31161069 0.84 STING1 (0.44) STING1MEN1MAPTKMT2AABCB1
SCHEMBL31160647 0.84 STING1 (0.44) STING1MEN1MAPTKMT2AABCB1
SCHEMBL31160649 0.84 STING1 (0.44) STING1MEN1MAPTKMT2AABCB1
SCHEMBL10903512 0.83 STING1 (0.46) STING1MEN1MAPTKMT2AABCB1
SCHEMBL5524426 0.82 STING1 (0.44) STING1MEN1MAPTKMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 — — US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 — — US disclosed
EP-2739613-A2 FLAVONOID COMPOUNDS Cardero Therapeutics, Inc. (US) 2014-06-11 — — EP disclosed
WO-2013022846-A2 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2013-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256741-A1 FLAVONOID COMPOUNDS FIS1, TFAM, MFN2 STING1 2452/4885MEN1 4747/4885MAPT 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback